Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children
Journal: Neurology; June 13, 2024
Author(s): James A. Varley, Dimitrios Champsas, Timothy Prossor, Giuseppe Pontillo, Omar Abdel-Mannan, Zhaleh Khaleeli, Axel Petzold, Ahmed T. Toosy, Sachid A. Trip, Heather Wilson, Dermot H. Mallon, Cheryl Hemingway, Kshitij Mankad, Michael Kin Loon Chou Andrew J. Church, Melanie S. Hart, Michael P. Lunn, Wallace Brownlee, Yael Hacohen, and Olga Ciccarelli
Testing the validity of the 2023 International Diagnostic Criteria for MOGAD in a selected group of adults and children
In 2023, international experts in the field of neuroimmunology came in agreement and published international diagnostic criteria for MOGAD.
This study aimed to validate those diagnostic criteria in real-world clinical settings. The authors used data of 539 patients (135 children and 404 adults) who had been diagnosed with MOGAD between 2018 and 2022 in 2 specialist hospitals and reevaluated those patients’ cases against the new diagnostic criteria (that is, retrospectively). As per the results, MOGAD was accurately diagnosed when the criteria were followed. The accuracy of the criteria in this regard was comparable with the best judgment of expert neurologists. The diagnostic accuracy achieved when the criteria were followed was better for children than for adults. Apart from testing positive for anti-MOG antibodies, patients should show at least one clinical or MRI feature listed in the criteria.
Related article: Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
Free Access: Full text
